<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amifostine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amifostine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amifostine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8533" href="/d/html/8533.html" rel="external">see "Amifostine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11455" href="/d/html/11455.html" rel="external">see "Amifostine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F132861"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ethyol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1044992"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Cisplatin</span>;</li>
<li>
<span class="list-set-name">Cytoprotective Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812480"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Refer to individual protocols. Amifostine doses &gt;300 mg/m<sup>2</sup> are associated with a moderate emetic potential; depending on the amifostine dose, antiemetics may be recommended to prevent nausea/vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="38abdab2-10ba-4dc2-9086-177e06f338ed">Cytoprotective agent against cisplatin or high-dose alkylating agents</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytoprotective agent against cisplatin or high-dose alkylating agents:</b> Limited data available: Efficacy results variable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gastrointestinal and hematologic toxicity reduction:</i> Infants, Children, and Adolescents: IV: 740 mg/m<sup>2</sup>/dose once daily prior to cytotoxic chemotherapy. In a study of patients (n=11, age range: 2.5 months to 17 years) receiving the same combination chemotherapy at the same doses (including cisplatin or high-dose alkylating agent) with or without amifostine, patients who received amifostine had significantly reduced incidences of mucositis and gastrointestinal toxicities and a significantly reduced requirement for erythrocyte transfusions. However, there was no difference in the number of platelet transfusions required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19214974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19214974'])">Ref</a></span>). In another study in osteosarcoma patients treated with cisplatin or carboplatin as part of combination chemotherapy, there was a reduction in neutrophil and leukocyte toxicity in patients who received amifostine (n=17) compared to those who did not (n=19); however, amifostine did not protect against platelet effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11990304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11990304'])">Ref</a></span>). Other studies have not shown protection against myelosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7664282','lexi-content-ref-16382125']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7664282','lexi-content-ref-16382125'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nephrotoxicity reduction:</i> Children and Adolescents: IV: 740 mg/m<sup>2</sup>/dose given immediately prior to cisplatin. In a small study of intracavitary cisplatin therapy for solid tumors, three patients (ages: 2 to 6 years) received amifostine. Of these patients, only one experienced persistent renal dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20658616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20658616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Reduction of platinum-induced hearing loss:</i> Children and Adolescents 3 to 20 years: IV: 600 mg/m<sup>2</sup>/dose given immediately prior to and 3 hours into cisplatin administration has been shown to reduce cisplatin-induced hearing loss in patients with average-risk medulloblastoma. Amifostine did not protect against hearing loss in patients with high-risk medulloblastoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18669462','lexi-content-ref-24414535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18669462','lexi-content-ref-24414535'])">Ref</a></span>). Other studies using a single dose of 740 mg/m<sup>2</sup> or 825 mg/m<sup>2</sup> immediately prior to cisplatin did not prevent ototoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19813275','lexi-content-ref-15999362','lexi-content-ref-11990304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19813275','lexi-content-ref-15999362','lexi-content-ref-11990304'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15eb1d00-a9ba-42cb-a0cd-1afc1665de3c">Xerostomia, moderate to severe from radiation of the head and neck, reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Xerostomia, moderate to severe from radiation of the head and neck, reduction:</b> Limited data available: Children ≥7 years and Adolescents: SubQ: 200 mg once daily given 30 minutes prior to standard fraction radiation therapy. Dosing based on a small pilot study in pediatric patients who received subcutaneous amifostine (n=5, age range: 7 to 15 years) for a total of 129 injections. No grade 3 or 4 mucosal or skin reactions occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16395679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16395679'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic toxicity:</p>
<p style="text-indent:-2em;margin-left:8em;">Cutaneous reactions or mucosal lesions appearing outside of the injection site or radiation port: Discontinue.</p>
<p style="text-indent:-2em;margin-left:8em;">Bullous, edematous, or erythematous lesions on the palms or soles: Discontinue.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe acute allergic reaction: Discontinue permanently.</p></div>
<div class="block dorp drugH1Div" id="F52729593"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F52729594"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F132865"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8533" href="/d/html/8533.html" rel="external">see "Amifostine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Medications for the treatment of hypersensitivity reactions should be available during amifostine administration. Amifostine doses &gt;300 mg/m<sup>2</sup> are associated with a moderate emetic potential. Depending on the amifostine dose, antiemetics may be recommended to prevent nausea and vomiting. Antiemetics (including dexamethasone [20 mg IV] and a 5-HT<sub>3</sub> receptor antagonist) are recommended with amifostine doses used for cisplatin-induced renal toxicity. Verify that patients are not hypotensive or dehydrated prior to amifostine administration. For patients receiving higher amifostine doses, interrupt antihypertensive therapy for 24 hours before amifostine treatment; patients who cannot safely stop their antihypertensives for 24 hours should not receive amifostine.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22374c4e-f0db-43ef-bfc6-9c31ed1e90c0">Radiation proctitis in rectal cancer, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radiation proctitis in rectal cancer, prevention (off-label use):</b>
<b>IV:</b> 340 mg/m<sup>2</sup> once daily prior to radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26142468','lexi-content-ref-24615748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26142468','lexi-content-ref-24615748'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1fc299a-3c9c-486a-85d1-1446b6452c65">Renal toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal toxicity (cisplatin-induced):</b>
<b>IV:</b> 910 mg/m<sup>2</sup> once daily over 15 minutes 30 minutes prior to chemotherapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58ee7648-8260-47d8-aeb5-20569d3c6729">Xerostomia due to radiation therapy for head and neck cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Xerostomia due to radiation therapy for head and neck cancer: IV:</b> 200 mg/m<sup>2</sup> over 3 minutes once daily 15 to 30 minutes prior to standard fraction radiation therapy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991725"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989052"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F132835"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (ovarian cancer: 61% to 62%; head and neck cancer: 15%; generally transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (ovarian cancer: 96%; head and neck cancer: 53%), severe nausea and vomiting (ovarian cancer: 19%; head and neck cancer: 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Endocrine &amp; metabolic: Hypocalcemia (head and neck cancer: 1%; clinically significant)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, chest pain, extrasystoles, flushing, ischemic heart disease, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills, dizziness, drowsiness, malaise, sensation of cold</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, hiccups</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (includes bruising at injection site, erythema at injection site, inflammation at injection site, injection site pruritus, pain at injection site, rash at injection site, swelling at injection site, urticaria at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, dyspnea, hypoxia, sneezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, atrial fibrillation, atrial flutter, cardiac arrhythmia, DRESS syndrome, hypersensitivity reaction (includes chest discomfort, laryngeal edema, pruritus, rigors, urticaria), myocardial infarction, renal failure, seizure, Stevens-Johnson syndrome, supraventricular tachycardia, syncope, toxic epidermal necrolysis, transient hypertension</p></div>
<div class="block coi drugH1Div" id="F132849"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to amifostine, aminothiol compounds, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F132832"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cutaneous reactions: Serious cutaneous reactions (some fatal), including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, toxicoderma, exfoliative dermatitis, and drug reaction with biopsy-proven eosinophilia and system symptoms (DRESS) have been reported with amifostine. Cutaneous reactions may be delayed, developing up to weeks after treatment initiation. Cutaneous reactions have been reported more frequently when used as a radioprotectant.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) have been reported, including chest discomfort, cutaneous eruptions, chills, dyspnea, hypoxia, laryngeal edema, pruritus, pyrexia, and urticaria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Cases of clinically relevant hypocalcemia have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Severe hypotension with complications have been reported, including (but not limited to) apnea, atrial fibrillation/flutter, bradycardia, dyspnea, myocardial ischemia/infarction, seizures, syncope, renal failure, tachycardia, and respiratory/cardiac arrest. The mean time of onset of hypotension was 14 minutes after amifostine infusion initiation and the mean hypotension duration was 6 minutes; in most cases BP returned to normal within 15 minutes. Patients who are hypotensive or dehydrated should not receive amifostine. Infusions &gt;15 minutes are associated with a higher incidence of adverse effects. Interrupt antihypertensive therapy for 24 hours before amifostine treatment (monitor BP closely); patients who cannot safely stop their antihypertensives 24 hours before should not receive amifostine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chemotherapy/radiation therapy interference: Amifostine may interfere with the antitumor activity of chemotherapy or radiation therapy regimens. Unless within the context of a clinical trial, do not use amifostine in patients receiving definitive radiation therapy or in patients receiving chemotherapy for malignancies other than ovarian cancer in which chemotherapy can produce a significant survival benefit or cure. Data regarding interference with antitumor efficacy when amifostine is administered prior to cisplatin therapy in settings other than advanced ovarian cancer are limited. Data are also insufficient to exclude a tumor-protective effect in the definitive radiation therapy setting; amifostine was studied with standard fractionated radiotherapy and when ≥75% of both parotid glands were exposed to radiation. The safety and efficacy of amifostine on the incidence of xerostomia in the setting of combined chemotherapy and radiotherapy, and in the setting of accelerated or hyperfractionated therapy, have not been established.</p></div>
<div class="block foc drugH1Div" id="F132843"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ethyol: 500 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ethyol: 500 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F132828"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322980"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ethyol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $1,285.69</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612215"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Amifostine doses &gt;300 mg/m<sup>2</sup> are associated with a moderate emetic potential; depending on the amifostine dose, antiemetics may be recommended to prevent nausea/vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer amifostine doses ≥600 mg/m<sup>2</sup> as an IV intermittent infusion over 15 minutes since the 15-minute infusion is better tolerated than a more prolonged infusion. Administer 200 mg/m<sup>2</sup> dose as a 3-minute infusion. Patients should be kept in supine position during infusion and amifostine should be interrupted if the blood pressure decreases significantly from baseline or if the patient develops symptoms related to decreased cerebral or cardiovascular perfusion. Patients experiencing decreased blood pressure should receive a rapid infusion of NS and be kept supine or placed in the Trendelenburg position. Amifostine can be restarted if the blood pressure returns to the baseline level.</p>
<p style="text-indent:-2em;margin-left:4em;">SubQ: Administer dose 30 minutes prior to irradiation in abdominal wall; alternate sides; massage site locally following injection to reduce discomfort (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16395679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16395679'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F132846"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV: </b></p>
<p style="text-indent:-2em;margin-left:4em;">200 mg/m<sup>2</sup> dose: Administer over 3 minutes starting 15 to 30 minutes prior to radiation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">910 mg/m<sup>2</sup> dose: Administer over 15 minutes starting 30 minutes prior to cisplatin. Do not exceed 15 minutes; longer infusions are associated with a higher incidence of side effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients who are hypotensive or dehydrated should not receive amifostine. Patients should be adequately hydrated and kept in supine position during infusion. Assess BP every 5 minutes during amifostine infusion and as clinically indicated following administration (for infusion duration &lt;5 minutes, monitor BP before infusion, immediately after, and as clinically indicated thereafter). If hypotension occurs, place patient in the Trendelenburg position and administer NS via a separate IV line.</p>
<p style="text-indent:-2em;margin-left:4em;">Amifostine doses &gt;300 mg/m<sup>2</sup> are associated with a moderate emetic potential. Depending on the amifostine dose, antiemetics may be recommended to prevent nausea and vomiting. Antiemetics (including dexamethasone [20 mg IV] and a 5-HT<sub>3</sub> receptor antagonist) are recommended with amifostine doses used for cisplatin-induced renal toxicity.</p></div>
<div class="block sts drugH1Div" id="F132856"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Reconstituted solutions (500 mg/10 mL) and solutions diluted in NS (in polyvinyl chloride [PVC] bags) for infusion are chemically stable for up to 5 hours at room temperature (~25°C [~77°F]) or up to 24 hours refrigerated (2°C to 8°C [36°F to 46°F]).</p></div>
<div class="block usep drugH1Div" id="F53565327"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Reduction of cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer (FDA approved in adults); reduction of moderate to severe xerostomia from radiation treatment of the head and neck where the radiation port includes a substantial portion of the parotid glands (FDA approved in adults); has also been used as a cytoprotective agent to selectively protect normal tissues against toxicity due to cytotoxic chemotherapy. <b>Note: </b>The clinical data do not suggest the efficacy of cisplatin-based chemotherapy or radiation therapy for the approved indications is altered by amifostine. Data on the effects of amifostine on the efficacy of chemotherapy or radiotherapy in other settings is limited. Do not administer amifostine in other settings where chemotherapy can produce a significant survival benefit or cure, or in patients receiving definitive radiotherapy, unless within the context of a clinical study.</p></div>
<div class="block mst drugH1Div" id="F132900"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Amifostine may be confused with amifampridine</p>
<p style="text-indent:-2em;margin-left:4em;">Ethyol may be confused with ethanol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298731"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F132837"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53617579"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who could become pregnant.</p></div>
<div class="block pri drugH1Div" id="F2930085"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to amifostine may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F53565328"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline blood pressure followed by a blood pressure reading every 5 minutes during the infusion and after administration if clinically indicated; monitor electrolytes, urinalysis, serum calcium, serum magnesium; monitor I &amp; O; evaluate for cutaneous reactions prior to each dose </p></div>
<div class="block pha drugH1Div" id="F132831"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically-active free thiol metabolite. The free thiol is available to bind to, and detoxify, reactive metabolites of cisplatin; and can also act as a scavenger of free radicals that may be generated (by cisplatin or radiation therapy) in tissues.</p></div>
<div class="block phk drugH1Div" id="F132848"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic dephosphorylation to two metabolites (active-free thiol and disulfide)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children: 9.3 minutes (Fouladi 2001); Adults: ~8 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (minimal; as amifostine and metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F132852"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A mi fu ting | An fu ding | Cytofos | Tian di da</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cytofos sun | Ethyol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Amiphos | Cytofos | Ethyol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amzuplar | Ethyol | Falvin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ethyol | Ethyol rt</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ethyol | Etiol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ethyol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-7664282">
<a name="7664282"></a>Adamson PC, Balis FM, Belasco JE, et al, “A Phase I Trial of Amifostine (WR-2721) and Melphalan in Children With Refractory Cancer,” <i>Cancer Res</i>, 1995, 55(18): 4069-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/7664282/pubmed" id="7664282" target="_blank">7664282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16395679">
<a name="16395679"></a>Anacak Y, Kamer S, Haydaroglu A. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers. <i>Pediatr Blood Cancer</i>. 2007;48:579-581.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/16395679/pubmed" id="16395679" target="_blank">16395679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16382125">
<a name="16382125"></a>Bernstein MJ, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: pediatric oncology group/children’s cancer group phase II study 9457 – a report from the Children’s Oncology Group. <i>Journal of Clinical Oncology</i>. 2006;24(1):152-159.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/16382125/pubmed" id="16382125" target="_blank">16382125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11013273">
<a name="11013273"></a>Brizel DM, Wasserman TH, Henke M, et al, “Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer,” <i>J Clin Oncol</i>, 2000, 18(19): 3339-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/11013273/pubmed" id="11013273" target="_blank">11013273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19214974">
<a name="19214974"></a>Cetingül N, Midyat L, Kantar M, Demirağ B, Aksoylar S, Kansoy S. Cytoprotective effects of amifostine in the treatment of childhood malignancies. <i>Pediatr Blood Cancer</i>. 2009;52:829-833.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/19214974/pubmed" id="19214974" target="_blank">19214974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32786044">
<a name="32786044"></a>Elad S, Cheng KKF, Lalla RV, et al; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i>. 2020;126(19):4423-4431. doi:10.1002/cncr.33100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/32786044/pubmed" id="32786044" target="_blank">32786044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ethyol.1">
<a name="Ethyol.1"></a>Ethyol (amifostine) [prescribing information]. Yardley, PA: Clinigen, Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18669462">
<a name="18669462"></a>Fouladi M, Chinagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. <i>J Clin Oncol</i>. 2008;26(22):3749-3755.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/18669462/pubmed" id="18669462" target="_blank">18669462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11550166">
<a name="11550166"></a>Fouladi M, Stempak D, Gammon J, et al. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. <i>Cancer.</i> 2001;92(4):914-923. doi:10.1002/1097-0142(20010815)92:4&lt;914::AID-CNCR1401&gt;3.0.CO;2-S<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/11550166/pubmed" id="11550166" target="_blank">11550166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24414535">
<a name="24414535"></a>Gurney JG, Bass JK, Onar-Thomas A, et al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. <i>Neuro Oncol</i>. 2014;16(6):848-855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/24414535/pubmed" id="24414535" target="_blank">24414535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19813275">
<a name="19813275"></a>Katzenstein HM, Chang KW, Krailo M, et.al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma. A report of the intergroup hepatoblastoma study P9645 as a part of the children’s oncology group. <i>Cancer</i>. 2009;115(24):5828-5835.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/19813275/pubmed" id="19813275" target="_blank">19813275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20658616">
<a name="20658616"></a>Katzenstein HM, Petricca S, Ricketts R, et al. Intracavitary cisplatin therapy for pediatric malignancies. <i>Pediatr Blood Cancer</i>. 2010;55:452-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/20658616/pubmed" id="20658616" target="_blank">20658616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24615748">
<a name="24615748"></a>Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i>. 2014;120(10):1453-1461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/24615748/pubmed" id="24615748" target="_blank">24615748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15999362">
<a name="15999362"></a>Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors. <i>Cancer</i>. 2005;104:841-847.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/15999362/pubmed" id="15999362" target="_blank">15999362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26142468">
<a name="26142468"></a>Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. <i>Ann Oncol.</i> 2015;26(suppl 5):v139-v151.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/26142468/pubmed" id="26142468" target="_blank">26142468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11990304">
<a name="11990304"></a>Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. <i>Journal of Pediatric Hematology/Oncology</i>. 2002;24(3):188-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/11990304/pubmed" id="11990304" target="_blank">11990304</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13399 Version 184.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
